Myfenax 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0051 
Minor change in labelling or package leaflet not 
22/09/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0048/G 
This was an application for a group of variations. 
23/06/2022 
26/06/2023 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IG/1508 
A.5.b - Administrative change - Change in the name 
23/05/2022 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
PSUSA/10550
Periodic Safety Update EU Single assessment - 
16/12/2021 
17/02/2022 
PL 
Refer to Scientific conclusions and grounds recommending 
/202105 
mycophenolate mofetil, mycophenolic acid 
the variation to terms of the Marketing Authorisation(s)’ for 
Page 2/13 
 
 
 
 
 
 
 
 
 
IB/0047 
C.I.2.a - Change in the SPC, Labelling or PL of a 
08/10/2021 
17/02/2022 
SmPC 
PSUSA/10550/202105. 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
N/0046 
Minor change in labelling or package leaflet not 
17/09/2021 
17/02/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0044 
B.III.1.a.2 - Submission of a new/updated or 
13/04/2021 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
PSUSA/10550
Periodic Safety Update EU Single assessment - 
10/12/2020 
19/02/2021 
SmPC 
Refer to Scientific conclusions and grounds recommending 
/202005 
mycophenolate mofetil, mycophenolic acid 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10550/202005. 
IA/0043 
A.7 - Administrative change - Deletion of 
01/02/2021 
17/02/2022 
Annex II and 
manufacturing sites 
PL 
IA/0041 
B.III.1.a.2 - Submission of a new/updated or 
17/06/2020 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IAIN/0040/G 
This was an application for a group of variations. 
12/06/2020 
18/11/2020 
SmPC, 
B.II.e.5.a.1 - Change in pack size of the finished 
Labelling and 
PL 
Page 3/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
IB/0039 
C.I.2.a - Change in the SPC, Labelling or PL of a 
16/03/2020 
18/11/2020 
SmPC, Annex 
generic/hybrid/biosimilar products following 
II and PL 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0038/G 
This was an application for a group of variations. 
11/12/2019 
18/11/2020 
SmPC, 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Labelling and 
PL 
IB/0035 
B.I.b.2.e - Change in test procedure for AS or 
04/12/2019 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
Page 4/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10550
Periodic Safety Update EU Single assessment - 
28/11/2019 
n/a 
PRAC Recommendation - maintenance 
/201905 
mycophenolate mofetil, mycophenolic acid 
IB/0036 
B.II.b.5.z - Change to in-process tests or limits 
22/10/2019 
n/a 
applied during the manufacture of the finished 
product - Other variation 
IA/0037 
B.II.e.3.a - Change in test procedure for the 
27/09/2019 
n/a 
immediate packaging of the finished product - Minor 
changes to an approved test procedure 
PSUSA/10550
Periodic Safety Update EU Single assessment - 
29/11/2018 
n/a 
PRAC Recommendation - maintenance 
/201805 
mycophenolate mofetil, mycophenolic acid 
IB/0033/G 
This was an application for a group of variations. 
14/09/2018 
04/10/2019 
SmPC, 
Labelling and 
PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0031 
B.III.1.a.2 - Submission of a new/updated or 
22/06/2018 
n/a 
Page 5/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
N/0030 
Minor change in labelling or package leaflet not 
19/03/2018 
04/10/2019 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
PSUSA/10550
Periodic Safety Update EU Single assessment - 
14/12/2017 
05/03/2018 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/201705 
mycophenolate mofetil, mycophenolic acid 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10550/201705. 
IA/0028 
B.III.1.a.2 - Submission of a new/updated or 
22/05/2017 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IA/0027 
A.7 - Administrative change - Deletion of 
13/04/2016 
12/04/2017 
Annex II and 
manufacturing sites 
PL 
IB/0026 
C.I.2.a - Change in the SPC, Labelling or PL of a 
28/01/2016 
18/02/2016 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II and PL 
IAIN/0025 
B.II.b.1.a - Replacement or addition of a 
02/12/2015 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0024/G 
This was an application for a group of variations. 
10/08/2015 
18/02/2016 
SmPC and PL 
Page 6/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0023 
C.I.2.a - Change in the SPC, Labelling or PL of a 
22/04/2015 
18/02/2016 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 7/13 
 
 
 
 
 
 
 
T/0022 
Transfer of Marketing Authorisation 
09/01/2015 
27/01/2015 
SmPC, 
Labelling and 
PL 
IB/0021 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
13/10/2014 
30/10/2014 
SmPC, 
life of the finished product - As packaged for sale 
(supported by real time data) 
Labelling and 
PL 
IB/0020 
C.I.2.a - Change in the SPC, Labelling or PL of a 
30/10/2013 
30/10/2014 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
IAIN/0019 
C.I.z - Changes (Safety/Efficacy) of Human and 
24/05/2013 
n/a 
Veterinary Medicinal Products - Other variation 
IA/0018 
B.III.1.a.2 - Submission of a new or updated Ph. Eur. 
01/02/2013 
n/a 
Certificate of Suitability to the relevant Ph. Eur. 
Monograph - Updated certificate from an already 
approved manufacturer 
IA/0017 
A.5.b - Administrative change - Change in the name 
21/11/2012 
n/a 
and/or address of a manufacturer of the finished 
product, including quality control sites (excluding 
manufacturer for batch release) 
R/0015 
Renewal of the marketing authorisation. 
20/09/2012 
19/11/2012 
SmPC, Annex 
Based on the review of the available information, the CHMP 
II, Labelling 
is of the opinion that the quality, the safety and the efficacy 
of this medicinal product continues to be adequately and 
Page 8/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and PL 
sufficiently demonstrated and therefore considers the 
benefit/risk profile of Myfenax continues to be favourable. 
The CHMP is also of the opinion that the renewal can be 
granted with unlimited validity. 
IB/0016 
C.I.2.a - Change in the SPC, Labelling or PL of a 
13/09/2012 
19/11/2012 
SmPC and PL 
Update of Section 4.5 of the SmPC to include information 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
regarding the interaction with proton pump inhibitors 
following the outcome of PSUR 18 assessment (covering 
period: 01.05.08-30.04.11) of the Reference Product. The 
Package Leaflet has been updated accordingly. 
IAIN/0014/G 
This was an application for a group of variations. 
16/03/2012 
11/06/2012 
Annex II and 
PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.2.b.1 - Change to batch release arrangements 
and quality control testing of the FP - Not including 
batch control/testing 
IA/0013 
B.III.1.a.2 - Submission of a new or updated Ph. Eur. 
15/09/2011 
n/a 
Certificate of Suitability to the relevant Ph. Eur. 
Monograph - Updated certificate from an already 
approved manufacturer 
IB/0012 
C.I.2.a - Change in the SPC, Labelling or PL of a 
10/02/2011 
n/a 
SmPC, Annex 
Changes to the PIL section 2 (Pregnancy and breast-
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
II and PL 
feeding) recommended by the CHMP following the 
assessment of the originator product. 
The MAH also took the opportunity to: 
-  Delete the version number of the DDPS from Annex IIB 
of the Marketing Authorisation. 
- Change the name of the active ingredient from 
"mycophenolate" to "mycophenolate mofetil" throughout 
Page 9/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
the SmPC and PIL. 
- Make minor linguistic changes to comply with QRD 
requirements. 
N/0010 
Minor change in labelling or package leaflet not 
12/11/2010 
n/a 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0011/G 
This was an application for a group of variations. 
21/10/2010 
21/10/2010 
SmPC, 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Labelling and 
PL 
N/0008 
Minor change in labelling or package leaflet not 
13/07/2010 
n/a 
PL 
connected with the SPC (Art. 61.3 Notification) 
II/0007 
Update of section 4.8 of the SPC to include 
21/01/2010 
23/03/2010 
SmPC 
In September 2009, a variation (EMEA/H/C/82/II/93) to 
information on isolated reports of interstitial lung 
disease and pulmonary fibrosis. This change was 
made to bring Myfenax's product information in line 
with the reference medicinal product CellCept. 
Update of Summary of Product Characteristics 
the marketing authorisation for CellCept was approved to 
update section 4.8 of the SPC to include information on 
isolated reports of ILD and pulmonary fibrosis. In 
November 2009, the Marketing Authorisation Holder for 
Myfenax submitted a Type II variation to bring the product 
information for Myfenax in line with CellCept's product 
information. 
II/0004 
Update of section 4.4 and 4.8 of the SPC to include 
23/07/2009 
21/08/2009 
SmPC and PL 
In April 2009, a variation (EMEA/H/C/82/II/86) to the 
information on pure red cell aplasia. Update of 
marketing authorisation for CellCept was approved to 
Page 10/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
sections 4.8 of the SPC to include information on 
acquired Pelger-Huet anomaly and to include the 
term "gingival hyperplasia". Update of section 4.5 of 
the SPC to include possible drug-drug interaction of 
Myfenax in combination with ciprofloxacin or 
amoxicillin plus clavulanic acid. The Package Leaflet 
was updated accordingly. These changes were made 
to bring Myfenax's product information in line with its 
reference medicinal product CellCept. 
Update of Summary of Product Characteristics and 
Package Leaflet 
update sections 4.4 and 4.8 of the SPC to include 
information on pure red cell aplasia; to update section 4.8 
of the SPC to include information on acquired Pelger-Huet 
anomaly and to include the term "gingival hyperplasia"; to 
update of section 4.5 of the SPC to include possible drug-
drug interaction of Myfenax in combination with 
ciprofloxacin or amoxicillin plus clavulanic acid. The 
Package Leaflet was updated accordingly. On 27 April 2009, 
the Marketing Authorisation Holder (MAH) for Myfenax was 
requested the submission of a Type II variation, within two 
months, to match the changes introduced by CellCept 
variation II/0086. In June 2009, the MAH submitted the 
requested Type II variation to bring the product information 
for Myfenax in line with CellCept's product information. 
IB/0006 
IB_17_a_Change in re-test period of the active 
15/07/2009 
n/a 
substance 
IA/0005 
IA_15_a_Submission of Ph. Eur. certificate for active 
01/07/2009 
n/a 
substance - approved manufacturer 
II/0003 
Inclusion (following adoption by the CHMP of a safety 
22/01/2009 
26/02/2009 
SmPC 
In October 2008, a variation (EMEA/H/C/82/II/84) to the 
variation to the Marketing Authorisation of the 
Innovator product, CellCept) of a new warning in 
sections 4.4 and 4.8 of the Myfenax's 
(mycophenolate mofetil) summary of product 
characteristics (SPC) related to cases of BK virus-
associated nephropathy, as well as cases of JC virus-
associated progressive multifocal 
leukoencephalopathy (PML) reported in patients 
treated with mycophenolate mofetil. 
marketing authorisation for CellCept was approved to 
update sections 4.4 and 4.8 of the SPC to implement the 
warning on BK virus associated nephropathy (BKVN) and JC 
virus associated progressive multifocal 
leukoencephalopathy (PML) requested by the CHMP in July 
2008. 
In 08 October 2008, the Marketing Authorisation Holder 
(MAH) for Myfenax was requested the submission of a Type 
II variation, within two months, to match the changes 
Page 11/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Update of Summary of Product Characteristics 
introduced by CellCept variations II/0084. In November 
2008, the MAH submitted the requested Type II variation 
to bring the SPC for Myfenax in line with CellCept's product 
information. 
IB/0002 
IB_34_b_01_Change in colour/flavour - Increase or 
02/12/2008 
n/a 
SmPC, 
addition: colouring system 
Labelling and 
PL 
II/0001 
Update of sections 4.4 and 4.8 of the Summary of 
26/06/2008 
25/07/2008 
SmPC and PL 
The reference medicinal product for Myfenax is CellCept 
product Characteristics (SPC) to include information 
that cases of Progressive Multifocal 
Leukoencephalopathy (PML), sometime fatal, have 
been reported in Myfenax treated patients. Section 
4.6 of the SPC was also updated to include that 
cases of spontaneous abortion have been reported in 
patients exposed to Myfenax. The Package Leaflet 
was updated accordingly. These changes were made 
to bring the Myfenax's product information in line 
with CellCept (reference medicinal product for 
Myfenax). 
In addition, the MAH corrected the contact details for 
Hungary and France in the "Marketing Authorisation 
Holder and Manufacturer" section of the Package 
Leaflet. 
Update of Summary of Product Characteristics and 
Package Leaflet 
(which was first granted marketing authorisation in the EU 
on 14 February 1996 for the prevention of renal transplant 
rejection when used in combination with ciclosporin and 
corticosteroids, and subsequently for prevention of cardiac 
and hepatic transplant rejection). 
On 28 February 2008, two variations 
(EMEA/H/C/000082/II/0082 and 
EMEA/H/C/000082/II/0083) to the Marketing Authorisation 
for CellCept were approved to update sections 4.4, and 4.8 
of the SPC to include information that cases of Progressive 
Multifocal Leukoencephalopathy (PML), sometimes fatal, 
have been reported in CellCept treated patients, and to 
update section 4.6 of the SPC to include that cases of 
spontaneous abortions have been reported in patients 
exposed to CellCept. 
On 11 March 2008, the Marketing Authorisation Holder 
(MAH) for Myfenax was requested the submission of a Type 
II variation, within two months, to match the changes 
introduced by CellCept variations II/0082 and II/0083.  On 
29 May 2008, the MAH submitted the requested Type II 
Page 12/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
variation to bring the SPC and PL for Myfenax in line with 
CellCept's product information. 
Page 13/13 
 
 
 
 
 
 
